Wedbush analyst Jay McCanless maintains Builders FirstSource (NYSE:BLDR) with a Outperform and raises the price target from $80 to $95.
EF Hutton Initiates Coverage On G1 Therapeutics with Buy Rating, Announces Price Target of $35
EF Hutton analyst Tony Butler initiates coverage on G1 Therapeutics (NASDAQ:GTHX) with a Buy rating and announces Price Target of $35.